The phase 3 trial demonstrated significant improvements in overall and progression-free survival, reinforcing the combination as a standard-of-care option across MMR subgroups.
Vicky Makker, MD
Advertisement
Articles by Vicky Makker, MD
Advertisement
Latest Updated Articles
KEYNOTE-775 Confirms Broad Efficacy of Lenvatinib Plus Pembrolizumab in Advanced Endometrial CancerPublished: October 21st 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Low-Dose Cannabinoids Show Potential to Restore Serotonin Levels and Reduce Inflammation in HIV, Study Finds
2
FDA Approves New Dosing Strength of Xolair Biosimilar, Omlyclo
3
MRD, ctDNA Testing May Help Diagnose Multiple Myeloma Precursor Conditions
4
Pharmacists Can Advance Lung Cancer Screening Awareness in High-Risk Patients
5
